Evidence map›Paper›PMID 33909687›Full record

ArticlePloS one2021

Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study.

Laurent Coudeville, Ombeline Jollivet, Cedric Mahé, Sandra Chaves, Gabriela B Gomez

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Measuring the Impact of Future Outbreaks? A Secondary Analysis of Routinely Available Data in Spain.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laurent CoudevilleModelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France.ORCID 0000-0003-3651-2959
Ombeline JollivetModelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France.
Cedric MahéModelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France.
Sandra ChavesModelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France.
Gabriela B GomezModelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France.ORCID 0000-0002-7409-798X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accelerated vaccine development in response to the COVID-19 pandemic should lead to a vaccine being available early 2021, albeit in limited supply and possibly without full vaccine acceptance. We assessed the short-term impact of a COVID-19 immunization program with varying constraints on population health and non-pharmaceutical interventions (NPIs) needs.

methodsA SARS-CoV-2 transmission model was calibrated to French epidemiological data. We defined several vaccine implementation scenarios starting in January 2021 based on timing of discontinuation of NPIs, supply and uptake constraints, and their relaxation. We assessed the number of COVID-19 hospitalizations averted, the need for and number of days with NPIs in place over the 2021-2022 period.

resultsAn immunisation program under constraints could reduce the burden of COVID-19 hospitalizations by 9-40% if the vaccine prevents against infections. Relaxation of constraints not only reduces further COVID-19 hospitalizations (30-39% incremental reduction), it also allows for NPIs to be discontinued post-2021 (0 days with NPIs in 2022 versus 11 to 125 days for vaccination programs under constraints and 327 in the absence of vaccination).

conclusionFor 2021, COVID-19 control is expected to rely on a combination of NPIs and the outcome of early immunisation programs. The ability to overcome supply and uptake constraints will help prevent the need for further NPIs post-2021. As the programs expand, efficiency assessments will be needed to ensure optimisation of control policies post-emergency use.

Indexed as

COVID-19COVID-19 VaccinesFranceHumansImmunization ProgramsModels, TheoreticalPandemicsSARS-CoV-2VaccinationVaccinesCOVID-19 VaccinesVaccines

Identifiers

PMID33909687
PMCPMC8081204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.